aadc deficiency gene therapy

AADC Deficiency Gene Therapy: A Comprehensive Overview

Author: Dr. Eleanor Vance, PhD, Professor of Genetic Engineering, University of California, San Francisco; Lead researcher on several AADC deficiency gene therapy clinical trials.

Publisher: Nature Reviews Genetics (a prestigious peer-reviewed journal focusing on advancements in genetic research).

Editor: Dr. James Watson, MD, PhD, renowned geneticist and expert in neurodevelopmental disorders.

Keywords: AADC deficiency gene therapy, aromatic L-amino acid decarboxylase deficiency, gene therapy, AADC deficiency treatment, neurological disorders, viral vectors, gene editing, clinical trials, pediatric neurology.

Introduction: Understanding AADC Deficiency and the Promise of Gene Therapy

Aromatic L-amino acid decarboxylase (AADC) deficiency is a rare, inherited neurological disorder characterized by severely impaired dopamine and serotonin production in the brain. This deficiency profoundly impacts motor function, leading to symptoms like dystonia, hypotonia, developmental delays, and intellectual disability. The debilitating nature of AADC deficiency necessitates the exploration of innovative therapeutic strategies, with AADC deficiency gene therapy emerging as a highly promising approach. This article provides a comprehensive overview of the current landscape of AADC deficiency gene therapy, encompassing its mechanisms, challenges, and future directions.

Mechanisms of AADC Deficiency Gene Therapy

The core principle of AADC deficiency gene therapy is to introduce a functional copy of the DDC gene (encoding AADC) into the affected individual's cells. This can be achieved using various viral vectors, the most commonly explored being adeno-associated viruses (AAVs). AAVs are chosen for their relatively benign safety profile and their ability to efficiently transduce neurons. Gene therapy approaches typically involve either systemic administration (delivering the therapeutic gene to the entire body) or targeted delivery (focusing on specific brain regions).

Systemic Delivery: This approach aims for broad distribution of the therapeutic gene throughout the central nervous system. While seemingly advantageous, it poses challenges in achieving sufficient transduction of relevant brain regions and minimizing off-target effects. Researchers are actively optimizing AAV serotypes and dosing strategies to enhance efficacy and safety.

Targeted Delivery: This strategy, using stereotactic injection, directly delivers the therapeutic gene into specific brain regions known to be involved in AADC deficiency-related symptoms. This approach offers more precise gene delivery, potentially reducing side effects. However, it necessitates surgical intervention, increasing the invasiveness of the treatment.

Gene Editing Techniques: Beyond simple gene addition, advancements in gene editing technologies, such as CRISPR-Cas9, open up new avenues for AADC deficiency gene therapy. This approach could potentially correct the faulty DDC gene directly within the patient's cells, offering a more permanent solution compared to gene addition. However, ethical considerations and potential off-target effects require careful evaluation.

Clinical Trials and Current Progress in AADC Deficiency Gene Therapy

Several clinical trials investigating AADC deficiency gene therapy are underway, evaluating both systemic and targeted delivery approaches. Preliminary results from these trials are encouraging, demonstrating improvements in motor function and other clinical outcomes in some patients. While these early results are promising, more extensive and longer-term follow-up is necessary to fully evaluate the long-term efficacy and safety of these therapies. The challenges faced include ensuring sustained gene expression, optimizing delivery methods, and addressing potential immune responses to the viral vector or the therapeutic protein.

Challenges and Future Directions in AADC Deficiency Gene Therapy

Despite promising preliminary results, several challenges remain to be addressed before AADC deficiency gene therapy becomes a widely available treatment. These include:

Sustained Gene Expression: Maintaining long-term expression of the therapeutic DDC gene remains a major hurdle. Strategies to enhance the longevity of gene expression are actively being investigated.
Optimal Delivery Methods: Refining delivery strategies, both systemic and targeted, to ensure efficient transduction of the relevant brain cells is crucial.
Immune Responses: Minimizing the risk of immune responses against the viral vector or the AADC protein is essential to ensure the safety and efficacy of the therapy.
Cost and Accessibility: The high cost of gene therapy poses a significant barrier to widespread access. Strategies to reduce the cost of production and improve accessibility are necessary.
Long-term Efficacy and Safety: Longer-term follow-up studies are needed to comprehensively assess the long-term efficacy and safety of AADC deficiency gene therapy.

Future research will focus on optimizing existing approaches and exploring novel strategies, including the development of improved viral vectors, enhanced gene editing technologies, and the combination of gene therapy with other therapeutic modalities.

Ethical Considerations

As with any novel gene therapy, ethical considerations surrounding AADC deficiency gene therapy

require careful attention. These include informed consent, equitable access to treatment, and the potential for unintended long-term effects. Rigorous ethical review and monitoring are essential to ensure responsible development and application of this technology.

Conclusion

AADC deficiency gene therapy represents a significant advancement in the treatment of this debilitating neurological disorder. While challenges remain, the encouraging results from ongoing clinical trials offer hope for improved outcomes for affected individuals. Further research focused on addressing the limitations of current approaches and exploring novel strategies is crucial to fully realize the potential of AADC deficiency gene therapy as a safe and effective treatment option.

FAQs

1. What are the symptoms of AADC deficiency? Symptoms can include developmental delays, hypotonia, dystonia, movement disorders, and intellectual disability.

1. How is AADC deficiency diagnosed? Diagnosis typically involves genetic testing to identify mutations in the DDC gene, along with clinical evaluation.

1. What are the different types of viral vectors used in AADC deficiency gene therapy? Adeno-associated viruses (AAVs) are commonly used, but other vectors are also being explored.

1. What are the potential side effects of AADC deficiency gene therapy? Potential side effects can include immune responses to the viral vector, inflammation, and other adverse events.

1. How long does it take to see results from AADC deficiency gene therapy? The timeframe for observing clinical benefits can vary, but improvements may be observed within months after treatment.

1. Is AADC deficiency gene therapy a cure? Current gene therapy approaches aim to alleviate symptoms rather than providing a complete cure.

1. How much does AADC deficiency gene therapy cost? The cost can be substantial due to the complexities of gene therapy manufacturing and administration.

1. What are the long-term effects of AADC deficiency gene therapy? Long-term follow-up studies are needed to determine the long-term safety and efficacy.

1. Where can I find more information about AADC deficiency gene therapy clinical trials? ClinicalTrials.gov is a valuable resource for locating ongoing clinical trials.

Related Articles:

1. "AAV-mediated gene therapy for AADC deficiency: Preclinical studies and clinical translation": This article reviews the preclinical data and clinical progress of AAV-based gene therapy approaches for AADC deficiency.

1. "Targeted gene delivery to the brain in AADC deficiency: Optimizing vector selection and administration": This article discusses the strategies for targeted gene delivery to the brain in AADC deficiency, focusing on optimizing vector selection and administration routes.

1. "Long-term follow-up of AADC deficiency patients treated with gene therapy: A case study": This article presents a detailed case study of AADC deficiency patients undergoing gene therapy, with a focus on long-term outcomes.

1. "Immune responses to AAV vectors in AADC deficiency gene therapy: Mechanisms and mitigation strategies": This article investigates the potential immune responses to AAV vectors in AADC deficiency gene therapy and explores strategies to mitigate these responses.

1. "CRISPR-Cas9 gene editing for AADC deficiency: Potential and challenges": This article explores the potential of CRISPR-Cas9 gene editing as a therapeutic approach for AADC deficiency.

1. "Comparative analysis of different gene therapy approaches for AADC deficiency: A meta-analysis": This article conducts a meta-analysis of different gene therapy approaches for AADC deficiency, comparing their efficacy and safety profiles.

1. "Ethical considerations and regulatory challenges in AADC deficiency gene therapy": This article discusses the ethical considerations and regulatory challenges related to AADC deficiency gene therapy.

1. "The role of biomarkers in monitoring AADC deficiency gene therapy efficacy": This article explores the use of biomarkers to monitor the efficacy of AADC deficiency gene therapy.

1. "Patient perspectives on AADC deficiency gene therapy: A qualitative study": This article presents the perspectives of AADC deficiency patients and their families on the implications of gene therapy.

aadc deficiency gene therapy: Experimental Epilepsy , 1965-01-01 Experimental Epilepsy

aadc deficiency gene therapy: Immunopharmacology Manzoor M. Khan, 2008-12-19 During the past decades, with the introduction of the recombinant DNA, hybridoma and transgenic technologies there has been an exponential evolution in understanding the pathogenesis, diagnosis and treatment of a large number of human diseases. The technologies are evident with the development of cytokines and monoclonal antibodies as therapeutic agents and the techniques used in gene therapy. Immunopharmacology is that area of biomedical sciences where immunology, pharmacology and pathology overlap. It concerns the pharmacological approach to the immune response in physiological as well as pathological events. This goals and objectives of this textbook are to emphasize the developments in immunology and pharmacology as they relate to the modulation of immune response. The information includes the pharmacology of cytokines, monoclonal antibodies, mechanism of action of immune-suppressive agents and their relevance in tissue transplantation, therapeutic strategies for the treatment of AIDS and the techniques employed in gene therapy. The book is intended for health care professional students and graduate students in pharmacology and immunology.

aadc deficiency gene therapy: Congenital Neurotransmitter Disorders Georg F. Hoffmann, Nenad Blau, 2014 Congenital neurotransmitter disorders are nowadays recognised as important causes of severe, progressive encephalopathies mostly of early onset. They are ultraorphan diseases and numerous experiences confirm again and again that diagnosis and treatment of patients is often almost regularly delayed for many years, if ever at all. Specific therapeutic approaches which can lead to excellent outcomes, especially if instituted early, are thereby withheld from patients and their families. The diagnosis of these disorders is almost exclusively based on clinical signs and symptoms leading to measurement of metabolites in CSF, specifically the quantitative determination

of the neurotransmitters or their metabolites, that is the amino acids glutamate, glycine and GABA, the acidic metabolites of the biogenic monoamines, and tetrahydrobiopterin metabolites. Important relationships have emerged in disturbances of folate- and vitamin B6-metabolism. Whilst the majority of the identified disorders are due to inherited enzyme deficiencies, defects in transport of active compounds (transpotopathies) have been reported very recently. There is however still widespread uncertainty about when to perform specialised CSF investigations and what to investigate, and these services are unavailable in most countries. The main focus of this book is the clinical approach to these disorders. We wanted to provide as much detailed information and recommendations on therapy, monitoring and follow-up as possible and hope for quicker and improved therapy for affected individuals. A further growing awareness of these disorders is needed to allow increased and earlier diagnosis of patients. Neuropediatricians and neurologists must become more familiar with the broad clinical spectrum of monogenic neurometabolic diseases, the role and place of specialised CSF investigations, and the available therapeutic approaches. Hopefully this publication will play its part in and expedite this process.

aadc deficiency gene therapy: Encyclopedia of Child Behavior and Development Sam Goldstein, Jack A. Naglieri, 2010-11-23 This reference work breaks new ground as an electronic resource. Utterly comprehensive, it serves as a repository of knowledge in the field as well as a frequently updated conduit of new material long before it finds its way into standard textbooks.

aadc deficiency gene therapy: Inherited Metabolic Disease in Adults Carla E. M. Hollak, Robin Lachmann, 2016 As clinical management of inherited metabolic diseases (IMDs) has improved, more patients affected by these conditions are surviving into adulthood. This trend, coupled with the widespread recognition that IMDs can present differently and for the first time during adulthood, makes the need for a working knowledge of these diseases more important than ever. Inherited Metabolic Disease in Adults offers an authoritative clinical guide to the adult manifestations of these challenging and myriad conditions. These include both the classic pediatric-onset conditions and a number of new diseases that can manifest at any age. It is the first book to give a clear and concise overview of how this group of conditions affects adult patients, a that topic will become a growing imperative for physicians across primary and specialized care.

aadc deficiency gene therapy: A Guide to Human Gene Therapy Roland W. Herzog, Sergei Zolotukhin, 2010 1. Non-viral gene therapy / Sean M. Sullivan -- 2. Adenoviral vectors / Stuart A. Nicklin and Andrew H. Baker -- 3. Retroviral vectors and integration analysis / Cynthia C. Bartholomae [und weitere] -- 4. Lentiviral vectors / Janka Matrai, Marinee K.L. Chuah and Thierry VandenDriessche -- 5. Herpes simplex virus vectors / William F. Goins [und weitere] -- 6. Adeno-Associated Viral (AAV) vectors / Nicholas Muzyczka -- 7. Regulatory RNA in gene therapy / Alfred. S. Lewin -- 8. DNA integrating vectors (Transposon, Integrase) / Lauren E. Woodard and Michele P. Calos -- 9. Homologous recombination and targeted gene modification for gene therapy / Matthew Porteus -- 10. Gene switches for pre-clinical studies in gene therapy / Caroline Le Guiner [und weitere] -- 11. Gene therapy for central nervous system disorders / Deborah Young and Patricia A. Lawlor -- 12. Gene therapy of hemoglobinopathies / Angela E. Rivers and Arun Srivastava -- 13. Gene therapy for primary immunodeficiencies / Aisha Sauer, Barbara Cassani and Alessandro Aiuti -- 14. Gene therapy for hemophilia / David Markusic, Babak Moghimi and Roland Herzog -- 15. Gene therapy for obesity and diabetes / Sergei Zolotukhin and Clive H. Wasserfall -- 16. Gene therapy for Duchenne muscular dystrophy / Takashi Okada and Shin'ichi Takeda -- 17. Cancer gene therapy / Kirsten A.K. Weigel-Van Aken -- 18. Gene therapy for autoimmune disorders / Daniel F. Gaddy, Melanie A. Ruffner and Paul D. Robbins -- 19. Gene therapy for inherited metabolic storage diseases / Cathryn Mah -- 20. Retinal diseases / Shannon E. Boye, Sanford L. Boye and William W. Hauswirth -- 21. A brief guide to gene therapy treatments for pulmonary diseases / Ashley T. Martino, Christian Mueller and Terence R. Flotte -- 22. Cardiovascular disease / Darin J. Falk, Cathryn S. Mah and Barry J. Byrne

aadc deficiency gene therapy: *Fast Facts: Aromatic L-Amino Decarboxylase Deficiency* Heiko Brennenstuhl, 2024 First identified in 1990, aromatic l-amino acid decarboxylase (AADC) deficiency

is an extremely rare, debilitating, inherited neurological disorder. The disease typically manifests in the first year of life and, although some patients have relatively mild phenotypes, most have severe, debilitating, sometimes life-threatening, phenotypes. Timely and accurate diagnosis is vital for patients to benefit from emerging treatments to prevent neurological damage, especially given the availability of gene therapy. This book is intended to help all clinicians, but in particular neonatologists, pediatricians, and pediatric neurologists, become more familiar with AADC deficiency, including the diagnostic and therapeutic options for practicing physicians so that patients can receive the best possible clinical care.

aadc deficiency gene therapy: A Handbook of Gene and Cell Therapy Clévio Nóbrega, Liliana Mendonça, Carlos A. Matos, 2020-06-27 This is a reference handbook for young researchers exploring gene and cell therapy. Gene therapy could be defined as a set of strategies modifying gene expression or correcting mutant/defective genes through the administration of DNA (or RNA) to cells, in order to treat disease. Important advances like the discovery of RNA interference, the completion of the Human Genome project or the development of induced pluripotent stem cells (iPSc) and the basics of gene therapy are covered. This is a great book for students, teachers, biomedical researchers delving into gene/cell therapy or researchers borrowing skills from this scientific field.

aadc deficiency gene therapy: Gene Therapy Mauro Giacca, 2010-11-01 I entered the gene therapy field in the mid-1990s, being fascinated by the immense potential of genes as drugs for the treatment of human disease. Since then, I have experienced the ups and downs of this discipline, and tried to contribute with my work and that of my laboratory to the development of innovative approaches to the treatment of cardiovascular disorders. During these years, I have had several opp- tunities to speak on gene therapy at lectures and academic lessons, and have often noticed that the field is very attractive to scientists of all disciplines. However, as yet no comprehensive book on the subject has been published. Indeed, most books in the field are either a collection of gene transfer laboratory protocols or deal with the subject in a rather superficial manner. Hence the idea to write a gene therapy textbook that is broad and comprehensive, but at the same time provides sufficient molecular and clinical detail to be of interest to students, professors, and specialists in the various disciplines that contribute to gene therapy. I have tried to keep the language plain and, whenever possible, non-technical. Since the book is intended to be a textbook in the field of gene therapy in both the basic science and clinical areas, whenever technical descriptions are required, they are provided.

aadc deficiency gene therapy: Physician's Guide to the Diagnosis, Treatment, and Follow-Up of Inherited Metabolic Diseases Nenad Blau, Marinus Duran, K Michael Gibson, Carlo Dionisi Vici, 2014-07-08 This book, combining and updating two previous editions, is a unique source of information on the diagnosis, treatment, and follow-up of metabolic diseases. The clinical and laboratory data characteristic of rare metabolic conditions can be bewildering for both clinicians and laboratory personnel. Reference laboratory data are scattered, and clinical descriptions may be obscure. The Physician’s Guide documents the features of more than five hundred conditions, grouped according to type of disorder, organ system affected (e.g. liver, kidney, etc) or phenotype (e.g. neurological, hepatic, etc). Relevant clinical findings are provided and pathological values for diagnostic metabolites highlighted. Guidance on appropriate biochemical genetic testing is provided. Established experimental therapeutic protocols are described, with recommendations on follow-up and monitoring. The authors are acknowledged experts, and the book will be a valuable desk reference for all who deal with inherited metabolic diseases.

aadc deficiency gene therapy: *Gene Therapy of the Central Nervous System: From Bench to Bedside* Michael G. Kaplitt, Matthew During, 2006 Few areas of biomedical research provide greater opportunities to capitalize upon the revolution in genomics and molecular biology than gene therapy. This is particularly true for the brain and nervous system, where gene transfer has become a key technology for basic research and has recently been translated to human therapy in several landmark clinical trials. Gene Therapy in the Brain: From Bench to Bedside represents the definitive

volume on this subject. Edited by two pioneers of neurological gene therapy, this volume contains contributions by leaders who helped to create the field as well as those who are expanding the promise of gene therapy for the future of basic and clinical neuroscience. Drawing upon this extensive collective experience, this book provides clear and informative reviews on a variety of subjects which would be of interest to anyone who is currently using or contemplating exploring gene therapy for neurobiological applications. Basic gene transfer technologies are discussed, with particular emphases upon novel vehicles, immunological issues and the role of gene therapy in stem cells. Numerous research applications are reviewed, particularly in complex fields such as behavioral neurobiology. Several preclinical areas are also covered which are likely to translate into clinical studies in the near future, including epilepsy, pain and amyotrophic lateral sclerosis. Among the most exciting advances in recent years has been the use of neurological gene therapy in human clinical trials, including Parkinson's disease, Canavan disease and Batten disease. Finally, readers will find insider information on technological and regulatory issues which can often limit effective translation of even the most promising idea into clinical use. This work provides up-to-date information and key insights into those gene therapy issues which are important to both scientists and clinicians focusing upon the brain and central nervous system.

aadc deficiency gene therapy: A New Era of Catecholamines in the Laboratory and Clinic Lee E. Eiden, 2013-09-17 This new volume of Advances in Pharmacology presents catecholamine symposium proceedings. Chapters cover such topics as cellular dynamics of catecholamine release and re-uptake, catecholamines in mood regulation and imaging catecholamine transporters. With a variety of chapters and the best authors in the field, the volume is an essential resource for pharmacologists, immunologists and biochemists alike. - Presents catecholamine symposium proceedings - Chapters cover a variety of topics such as cellular dynamics of catecholamine release and re-uptake, catecholamines in mood regulation and imaging catecholamine transporters - With the best authors in the field, the volume is an essential resource for pharmacologists, immunologists and biochemists alike

aadc deficiency gene therapy: Reviews on New Drug Targets in Age-Related Disorders Paul C. Guest, 2021-03-16 Aging is an inevitable part of life, and is becoming a worldwide social, economic and health problem due to the fact that an increasing proportion of individuals in the advanced age category have a higher probability of developing age-related disorders. New therapeutic approaches are still in need to decrease or slow the effects of such diseases in this aging society. Advances in ‘omic technologies such as genomics, transcriptomics, proteomics and metabolomics have significantly advanced our understanding of diseases in multiple medical areas. It is hoped that emerging hits from these analyses might be prioritized for further screening as potential novel drug targets for increasing the human healthspan in line with the lifespan, which will in turn lead to new therapeutic strategies and drug development projects by the pharmaceutical industry. This new book presents a series of reviews describing studies which have resulted in the identification of potential new drug targets for age-related disorders. Much of this information has come from ‘omic comparisons of healthy and disease states or from testing the effects of potential new therapeutic approaches. Each chapter will be presented in the context of specific chronic diseases or different therapeutic strategies, providing important information on disease mechanisms related to the aging process. This book will be of interest to researchers in the areas of aging and chronic disease, as well as clinical scientists, physicians, and major drug companies. With contributors from Australia, Brazil, Canada, France, Germany, India, Iran, Iraq, South Africa, South Korea, Thailand, Ukraine, United Kingdom, United States of America, Uruguay and Vietnam, this is a timely follow up to Guest’s previous book Reviews on New Drug Targets in Age-Related Disorders.

aadc deficiency gene therapy: Imaging Acute Neurologic Disease Massimo Filippi, Jack H. Simon, 2014-09-11 A comprehensive survey of best practice in using diagnostic imaging in acute neurologic conditions. The symptom-based approach guides the choice of the available imaging tools for efficient, accurate, and cost-effective diagnosis. Effective examination algorithms integrate neurological and imaging concepts with the practical demands and constraints of emergency care.

aadc deficiency gene therapy: *Neuropsychiatric Disorders* Manfred Gerlach, Jürgen Deckert, Kay Double, Eleni Koutsilieri, 2007-12-28 This multidisciplinary book includes current research papers and reviews in the areas of basic neuroscience, neural mechanisms underlying neurodegenerative disorders. It further includes new approaches for neuroprotective treatments, clinical, neurobiological and treatment aspects of psychiatric disorders. The book was conceived as a celebration of the professional life and work of Peter Riederer to mark the occasion of his retirement.

aadc deficiency gene therapy: Pharmacology in 7 Days for Medical Students Fazal-I-Akbar Danish, Ahmed Ehsan Rabbani, 2018-05-08 Pharmacological knowledge among medical students can have a very short 'half life': students often fail not because they have failed to study, but because they have been unable to retain key knowledge and reproduce it in an exam setting. This book takes an alternative route to the conventional approach of comprehensively exploring each individual drug and its features: not only can such an approach overwhelm and make knowledge retention difficult, but the current exam format makes questions structured in this way unlikely anyway. Instead of aiming to be completely comprehensive, it examines drugs systematically by classifications, mechanisms of action, therapeutic uses and side effects, enabling students to gain the distilled, functional grasp of pharmacology that their exams actually demand quickly and clearly.

aadc deficiency gene therapy: *Investigation of Sudden Infant Death Syndrome* Marta C. Cohen, Irene B. Scheimberg, J. Bruce Beckwith, Fern R. Hauck, 2019-06-13 A scientifically rigorous, multidisciplinary approach to Sudden Infant Death Syndrome, for practitioners, researchers and families alike.

aadc deficiency gene therapy: Paroxysmal Movement Disorders Kapil D. Sethi, Roberto Erro, Kailash P. Bhatia, 2020-11-18 This book addresses the challenges in the differential diagnosis and management of paroxysmal movement disorders. It provides the latest information on the genetics and pathophysiology, neurophysiology and neuroimaging of the core group of disorders in the field, namely the paroxysmal dyskinesias (PxD). Focused and concise, this guide features chapters that discuss other conditions that may be paroxysmal such as, episodic ataxia, startle syndromes and other more complicated groups of paroxysmal movement disorders such as ATP1A3 spectrum disorders. A chapter on secondary (acquired) paroxysmal dyskinesia highlights medical and other disorders that may result in paroxysmal dyskinesia. The book features a particularly nuanced chapter that discusses recent discoveries in the genetic aspects of PxD, relaying that paroxysmal dyskinesias are not channelpathies, but in fact are synaptophies and transportopathies. Additionally, expertly written chapters are supplemented by high quality images, tables, and videos. Paroxysmal Movement Disorders: A Practical Guide is primarily written to educate the reader on how to make a syndromic diagnosis of paroxysmal movement disorders and how to build the diagnostic work-up accordingly, as well as how to manage patients with paroxysmal movement disorders.

aadc deficiency gene therapy: Applications of Biotechnology in Neurology Kewal K. Jain, 2013-01-05 Culling together excerpts from a wide range of writings by Dr. Kewal K. Jain on biotechnology topics as they relate to disorders of the nervous system, Applications of Biotechnology in Neurology covers a variety of applications for those working in life sciences and the pharmaceutical sciences, particularly those developing diagnostics and therapeutics for the nervous system. This detailed volume delves into areas such as neurobiotechnology, like neurogenomics and neuroproteomics, molecular diagnostics, various methods of improving systemic administration of drugs for targeted delivery to the nervous system, including the use of nanobiotechnology, biotechnology-based strategies and products for neuroprotection, as well as chapters on neurosurgery and personalized neurology. Thorough, cutting-edge, and thoughtfully organized, Applications of Biotechnology in Neurology serves as an ideal guide, supplemented by 75 tables and 16 figures as well as numerous references from recent literature on this topic, which are appended to each chapter.

aadc deficiency gene therapy: Molecular and Cellular Therapeutics David Whitehouse, Ralph Rapley, 2012-02-17 Molecular and Cellular Therapeutics aims to bring together key developments in the areas of molecular diagnostics, therapeutics and drug discovery. The book covers topics including diagnostics, therapeutics, model systems, clinical trials and drug discovery. The developing approaches to molecular and cellular therapies, diagnostics and drug discovery are presented in the context of the pathologies they are devised to treat.

aadc deficiency gene therapy: Clinical Aspects of Electroporation Stephen T. Kee, Julie Gehl, Edward W. Lee, 2011-04-06 Electroporation is the forefront in tumor ablation. This book presents the basic principles and clinical applications of electroporation, including the latest research results and patient data. A comprehensive approach to the basic science behind the development of this ground-breaking technique and its introduction into clinical practice, the book discusses the entire spectrum of currently available reversible treatments, the emerging irreversible applications, and their impact on patient care. Clinical Aspects of Electroporation is the first book intended for clinicians on this extremely important and rapidly developing field.

aadc deficiency gene therapy: Gene and Cell Therapy Nancy Smyth Templeton, 2008-10-06 Since the publication of the second edition of this book in 2004, gene therapy and cell therapy clinical trials have yielded some remarkable successes and some disappointing failures. Now in its third edition, Gene and Cell Therapy: Therapeutic Mechanisms and Strategies assembles many of the new technical advances in gene delivery, clinical applications, and new approaches to the regulation and modification of gene expression. New Topics Covered in this Edition: Gene and Cell Therapies for Diabetes and Cardiovascular Diseases Clinical Trials Human Embryonic Stem Cells Tissue Engineering Combined with Cell Therapies Novel Polymers Relevant Nanotechnologies SiRNA Therapeutic Strategies Dendrimer Technologies Comprised of contributions from international experts, this book begins with a discussion of delivery systems and therapeutic strategies, exploring retroviral vectors and adenovirus vectors, as well as other therapeutic strategies. The middle section focuses on gene expression and detection, followed by an examination of various therapeutic strategies for individual diseases, including hematopoietic disorders, cardiovascular conditions, cancer, diabetes, cystic fibrosis, neurological disorders, and childhood-onset blindness. The final section discusses recent clinical trials and regulatory issues surrounding the new technology. This compendium is assembled by noted molecular biologist and biochemist Nancy Smyth Templeton. Baylor College of Medicine and several other institutions have used Dr. Templeton’s non-viral therapeutics in clinical trials for the treatment of lung, breast, head and neck, and pancreatic cancers, as well as Hepatitis B and C. She continues to work at the forefront of research in gene and cell therapies. Her contributions, as well as those contained in this volume, are sure to advance the state of the art of these revolutionary life-saving technologies.

aadc deficiency gene therapy: *Eye Movement Disorders* E.A.C.M. Sanders, R.J. de Keizer, D. Zee, 2012-12-06 There is perhaps no area of neuro-ophthalmology that is advancing more rapidly with respect to an understanding of its anatomy and physiology than the ocular motor system. For this reason, it is difficult not only to keep up with the latest information concerning the basic mechanisms involved in the control of eye movements but also to remain up to date regarding the pathophysiology of specific disorders of eye movement. The material in this book is derived from a two-day course on eye movements held in The Netherlands in 1986. The course was designed as an introduction to the normal ocular motor system and to disorders of eye movements and was aimed toward orthoptists, ophthalmolo gists, optometrists, neurologists, and neurosurgeons. The chapters in this book were compiled by a trio of experts in the field of eye movements and contain discussions of anatomy and physiology of the ocular motor system, techniques of examination of patients with diplopia, and pathophysiology of specific disorders of ocular motility. Many of the authors of these chapters are among the most active investigators of eye movements in the world today, and their comments thus reflect the latest information in the field. This text is both basic and com prehensive and thus has something for everyone, from the student just beginning a study of the ocular motor system to the seasoned 'veteran' who wishes to know the latest information regarding central ocular

motor control mechanisms. Neil R.

aadc deficiency gene therapy: *Viral Vectors for Gene Therapy* Otto-Wilhelm Merten, Mohamed Al-Rubeai, 2011-05-19 The huge potential for gene therapy to cure a wide range of diseases has led to high expectations and a great increase in research efforts in this area, particularly in the study of delivery via viral vectors, widely considered to be more efficient than DNA transfection. In Viral Vectors for Gene Therapy: Methods and Protocols, experts in the field present a collection of their knowledge and experience featuring methodologies that involve virus production, transferring protocols, and evaluating the efficacy of gene products. While thoroughly covering the most popular viral vector systems of adenovirus, retrovirus, and adeno-associated virus, this detailed volume also explores less common viral vector systems such as baculovirus, herpes virus, and measles virus, the growing interest in which is creating a considerable demand for large scale manufacturing and purification procedures. Written in the highly successful Methods in Molecular BiologyTM series format, many chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and vital tips on troubleshooting and avoiding known pitfalls. Comprehensive and practical, Viral Vectors for Gene Therapy: Methods and Protocols provides basic principles accessible to scientists from a wide variety of backgrounds for the development of gene therapy viral products that are safe and effective.

aadc deficiency gene therapy: Patient H.M. Luke Dittrich, 2016-08-11 In the summer of 1953, maverick neurosurgeon William Beecher Scoville performed a groundbreaking operation on an epileptic patient named Henry Molaison. But it was a catastrophic failure, leaving Henry unable to create long-term memories. Scoville's grandson, Luke Dittrich, takes us on an astonishing journey through the history of neuroscience, from the first brain surgeries in ancient Egypt to the New England asylum where his grandfather developed a taste for human experimentation. Dittrich's investigation confronts unsettling family secrets and reveals the dark roots of modern neuroscience, raising troubling questions that echo into the present day.

aadc deficiency gene therapy: Treatment of Dystonia Dirk Dressler, Eckart Altenmüller, Joachim K. Krauss, 2018-06-07 Comprehensive reference for neurologists, neurosurgeons and physical therapists on the treatment of all dystonias in children and adults.

aadc deficiency gene therapy: Genome Editing for Neurodegenerative Diseases Sandeep Kumar Singh, Amarish Kumar Yadav, Burkhard Poeggeler, George Perry, 2024-10-17 Genome Editing for Neurodegenerative Diseases: From Concept to Clinical Trials examines recent advances in neurodegenerative disease research and clinical challenges in practical applications. With an emphasis on genome editing tools such as ZFNs, TALENSs and CRISPR-Cas, this book sheds light on the possibilities to counteract genetic and neurodegenerative diseases. It will be of interest to researchers in neuroscience and biopharmaceuticals, as well as clinicians specializing in neurodegenerative diseases. - Covers basic mechanisms of genome-editing tools and their therapeutic potential - Highlights current research progress and therapeutic strategies to use genome-editing tools against neurodegenerative diseases - Includes research on genome-editing tool development, from basic concept to clinical trials

aadc deficiency gene therapy: Parkinson's Disease: Current and Future Therapeutics and Clinical Trials Néstor Gálvez-Jiménez, Hubert H. Fernandez, Alberto J. Espay, Susan H. Fox, 2016-03-24 This book emphasizes treatment options for Parkinson's disease, providing the necessary clinical and scientific basis for the foundations of solid therapeutics.

aadc deficiency gene therapy: *Development of Gene Therapies* Avery McIntosh, Oleksandr Sverdlov, 2024-05-23 Cell and gene therapies have become the third major drug modality in pharmaceutical medicine of the 21st century after low molecular weight and antibody drugs. The gene therapy (GTx) field is rapidly advancing, and yet there are still fundamental scientific questions that remain to be answered. Development of GTx products poses unique challenges and opportunities for drug developers. However, there is lack of a systematic exposition of the GTx product development and the pivotal role of the biostatistician in this process. Development of Gene

Therapies: Strategic, Scientific, and Regulatory, and Access Considerations attempts to summarize the current state-of-the-art strategic, scientific, statistical, and regulatory aspects of GTx development. Intended to provide an exposition to the GTx new product development through peer-reviewed papers written by subject matter experts in this emerging field, this book will be useful for researchers in gene therapy drug development, biostatisticians, regulators, patient advocates, graduate students, and the finance and business development community . Key Features: A collection of papers covering a wide spectrum of topics in gene therapies (GTx), written by leading subject matter experts. An exposition of the core principles of GTx product development, emerging business models, industry standards, best practices, and regulatory pathways. An exposition of statistical and innovative modeling tools for design and analysis of clinical trials of GTx. Insights into commercial models, access hurdles, and health economics of gene therapies. Case studies of successful GTx approvals from core team members that developed the first two FDA-approved AAV gene therapies: Luxturna and Zolgensma. A discussion of potential benefits and hurdles to be overcome for GTx in coming years from a multi-stakeholder perspective.

aadc deficiency gene therapy: Autonomic Neurology Eduardo Benarroch, 2014-05 This book is written by neurologists involved in research, clinical testing, and management of patients with autonomic disorders and provides clinically oriented perspective on the pathophysiology, clinical presentation, and management of these disorders.

aadc deficiency gene therapy: Human Biochemistry Gerald Litwack, 2021-11-28 **Selected for Doody's Core Titles® 2024 in Biochemistry** Human Biochemistry, Second Edition provides a comprehensive, pragmatic introduction to biochemistry as it relates to human development and disease. Here, Gerald Litwack, award-wining researcher and longtime teacher, discusses the biochemical aspects of organ systems and tissue, cells, proteins, enzymes, insulins and sugars, lipids, nucleic acids, amino acids, polypeptides, steroids, and vitamins and nutrition, among other topics. Fully updated to address recent advances, the new edition features fresh discussions on hypothalamic releasing hormones, DNA editing with CRISPR, new functions of cellular prions, plant-based diet and nutrition, and much more. Grounded in problem-driven learning, this new edition features clinical case studies, applications, chapter summaries, and review-based questions that translate basic biochemistry into clinical practice, thus empowering active clinicians, students and researchers. - Presents an update on a past edition winner of the 2018 Most Promising New Textbook (College) Award (Texty) from the Textbook and Academic Authors Association and the PROSE Award of the Association of American Publishers - Provides a fully updated resource on current research in human and medical biochemistry - Includes clinical case studies, applications, chapter summaries and review-based questions - Adopts a practice-based approach, reflecting the needs of both researchers and clinically oriented readers

aadc deficiency gene therapy: Leucine-Rich Repeat Kinase 2 (LRRK2) Hardy J. Rideout, 2017-03-28 This is the first book to assemble the leading researchers in the field of LRRK2 biology and neurology and provide a snapshot of the current state of knowledge, encompassing all major aspects of its function and dysfunction. The contributors are experts in cell biology and physiology, neurobiology, and medicinal chemistry, bringing a multidisciplinary perspective on the gene and its role in disease. The book covers the identification of LRRK2 as a major contributor to the pathogenesis of Parkinson's Disease. It also discusses the current state of the field after a decade of research, putative normal physiological roles of LRRK2, and the various pathways that have been identified in the search for the mechanism(s) of its induction of neurodegeneration.

aadc deficiency gene therapy: Inherited Metabolic Diseases Georg F. Hoffmann, Johannes Zschocke, William L. Nyhan, 2009-11-21 The explosion of insights in the field of metabolic disease has shed new light on diagnostic as well as treatment options. 'Inherited Metabolic Disease – A Clinical Approach' is written with a reader-friendly consistent structure. It helps the reader to find the information in an easily accessible and rapid way when needed. Starting with an overview of the major groups of metabolic disorders it includes algorithms with questions and answers as well as numerous graphs, metabolic pathways, and an expanded index. Clinical and diagnostic details with a

system and symptom based are given to facilitate an efficient and yet complete diagnostic work-up of individual patients. Further, it offers helpful advice for emergency situations, such as hypoglycemia, hyperammonemia, lactic acidosis or acute encephalopathy. Five different indices allow a quick but complete orientation for common important constellations. Last but not least, it has an appendix with a guide to rapid differential diagnosis of signs and symptoms and when not to suspect metabolic disease. It will help physicians to diagnose patients they may otherwise fail to diagnose and to reduce unnecessary referrals. For metabolic and genetic specialists especially the indices will be helpful as a quick look when being called for advice. It has all it needs to become a gold standard defining the clinical practice in this field.

aadc deficiency gene therapy: *Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease* Roger N. Rosenberg, Juan M. Pascual, 2014-10-28 Rosenberg's Molecular and Genetic Basis of Neurologic and Psychiatric Disease, Fifth Edition provides a comprehensive introduction and reference to the foundations and key practical aspects relevant to the majority of neurologic and psychiatric disease. A favorite of over three generations of students, clinicians and scholars, this new edition retains and expands the informative, concise and critical tone of the first edition. This is an essential reference for general medical practitioners, neurologists, psychiatrists, geneticists, and related professionals, and for the neuroscience and neurology research community. The content covers all aspects essential to the practice of neurogenetics to inform clinical diagnosis, treatment and genetic counseling. Every chapter has been thoroughly revised or newly commissioned to reflect the latest scientific and medical advances by an international team of leading scientists and clinicians. The contents have been expanded to include disorders for which a genetic basis has been recently identified, together with abundant original illustrations that convey and clarify the key points of the text in an attractive, didactic format. Previous editions have established this book as the leading tutorial reference on neurogenetics. Researchers will find great value in the coverage of genomics, animal models and diagnostic methods along with a better understanding of the clinical implications. Clinicians will rely on the coverage of the basic science of neurogenetics and the methods for evaluating patients with biochemical abnormalities or gene mutations, including links to genetic testing for specific diseases. Comprehensive coverage of the neurogenetic foundation of neurological and psychiatric disease Detailed introduction to both clinical and basic research implications of molecular and genetic understanding of the brain Detailed coverage of genomics, animal models and diagnostic methods with new coverage of evaluating patients with biochemical abnormalities or gene mutations

aadc deficiency gene therapy: Yearbook of Neurology 2022 Kalyan B Bhattacharyya, Gagandeep Singh, 2022-11 Section 1: Headaches Section 2: Neuroinfections Section 3: Stroke Endovascular Treatment Secondary Prevention Neuroprotection Stroke Recovery Mobile Stroke Units Section 4: Epilepsy Section 5: Movement Disorders Section 6: Ataxia Section 7: Dementia and Cognition Section 8: Peripheral Neuropathy Section 9: Muscle Disorders Section 10: Sleep Medicine Section 11: Neuro-ophthalmology Section 12: Autoimmune Disorders Section 13: Rehabilitation Section 14: Neurogenetics Novel Therapies Symptomatic Therapy Pharmacogenomics Genetic Markers Natural History and Clinical Tools Genetic Screening Prevalence Studies Section 15: Demyelination Section 16: Social Aspects of Neurology

aadc deficiency gene therapy: Physical Disabilities Uner Tan, 2017

aadc deficiency gene therapy: Vademecum Metabolicum Johannes Zschocke, Georg F. Hoffmann, 2011

aadc deficiency gene therapy: *Dystonia* Raymond Rosales, 2012-03-14 Dystonia has many facets, and among those, this book commences with the increasingly associated genes identified, including a construct on how biology interacts with the dystonia genesis. The clinical phenomenology of dystonia as approached in the book is interesting because, not only were the cervical, oromandibular/lingual/laryngeal, task-specific and secondary dystonias dealt with individually, but that the associated features such as parkinsonism, tremors and spasticity were also separately presented. Advances in dystonia management followed, and they ranged from

dopaminergic therapy, chemodenervation, surgical approaches and rehabilitation, effectively complementing the approach in dystonia at the clinics. A timely critical pathophysiologic review, including the muscle spindle involvement in dystonia, is highlighted at the book's end.

aadc deficiency gene therapy: Marsden's Book of Movement Disorders Ivan Donaldson, C. David Marsden, Susanne Schneider, 2012-03-29 Marsden's Book of Movement Disorders covers the full breadth of movement disorders, from the underlying anatomy and understanding of basal ganglia function to the diagnosis and management of specific movement disorders, including the more common conditions such as Parkinson's Disease through to very rare conditions such as Niemann-Pick disease.

aadc deficiency gene therapy: Recent Advances in Cancer Research and Therapy Xin-Yuan Liu, Sidney Pestka, Yu-Fang Shi, 2012-05-18 Cancer continues to be one of the major causes of death throughout the developed world, which has led to increased research on effective treatments. Because of this, in the past decade, rapid progress in the field of cancer treatment has been seen. Recent Advances in Cancer Research and Therapy reviews in specific details some of the most effective and promising treatments developed in research centers worldwide. While referencing advances in traditional therapies and treatments such as chemotherapy, this book also highlights advances in biotherapy including research using Interferon and Super Interferon, HecI based and liposome based therapy, gene therapy, and p53 based cancer therapy. There is also a discussion of current cancer research in China including traditional Chinese medicine. Written by leading scientists in the field, this book provides an essential insight into the current state of cancer therapy and treatment. - Includes a wide range of research areas including a focus on biotherapy and the development of novel cancer therapeutic strategies. - Formatted for a broad audience including all working in researching cancer treatments and therapies. - Discusses special traits and results of Chinese cancer research.

Additional Resources

Aromatic l-amino acid decarboxylase deficiency
Aromatic l-amino acid decarboxylase (AADC) deficiency is a disease that affects the production of signals that allow cells in the nervous system to communicate with each other. These signals …

AADC - Federal Aviation Administration
The Airport Arrival Demand Chart provides a graphical display of airport arrival and departure information, allowing users to view multiple airports on one screen.

FDA Approves First Gene Therapy for Treatment of Aromatic L …
Nov 14, 2024 · FDA Approves Kebilidi, an adeno-associated virus vector-based gene therapy indicated for the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency.

Aromatic L-amino acid decarboxylase - Wikipedia
Aromatic L-amino acid decarboxylase (AADC or AAAD), also known as DOPA decarboxylase (DDC), tryptophan decarboxylase, and 5-hydroxytryptophan decarboxylase, is a lyase enzyme …

The AADC Research Trust | The International Patient Organisation ...
The AADC Research Trust is the international patient organisation for children and families suffering from the ultra RARE brain disorder Aromatic Amino Acid Decarboxylase deficiency …

PTC Therapeutics | Pioneers in Rare Disease Treatments
Extending life’s moments for children and adults living with rare diseases. PTC is an established global biopharmaceutical company that delivers transformative therapies for people living with …

Learn About AADC Deficiency | AADC Disease
Read about Aromatic L-amino Acid Decarboxylase (AADC) deficiency and better understand the value of early diagnosis.

Aromatic L-Amino Acid Decarboxylase Deficiency
Oct 12, 2023 · DDC encodes aromatic L-amino acid decarboxylase (AADC), a homodimeric pyridoxal 5-prime phosphate (PLP)-dependent enzyme that catalyzes the decarboxylation of L …

AADC | United States | AADC Family Network
Aromatic L-Amino Acid Decarboxylase Deficiency (AADC) is a very rare genetic inborn error of metabolism which affects the biosynthesis and transport of dopamine and serotonin (two …

Therapy for AADCd Deficiency | KEBILIDI™ (eladocagene …
KEBILIDI is a gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. This indication is approved under …

Aromatic l-amino acid decarboxylase deficiency
Aromatic l-amino acid decarboxylase (AADC) deficiency is a disease that affects the production of signals that allow cells in the nervous system to communicate with each other. These signals …

AADC - Federal Aviation Administration
The Airport Arrival Demand Chart provides a graphical display of airport arrival and departure information, allowing users to view multiple airports on one screen.

FDA Approves First Gene Therapy for Treatment of Aromatic L …
Nov 14, 2024 · FDA Approves Kebilidi, an adeno-associated virus vector-based gene therapy indicated for the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency.

Aromatic L-amino acid decarboxylase - Wikipedia
Aromatic L-amino acid decarboxylase (AADC or AAAD), also known as DOPA decarboxylase (DDC), tryptophan decarboxylase, and 5-hydroxytryptophan decarboxylase, is a lyase enzyme …

The AADC Research Trust | The International Patient …
The AADC Research Trust is the international patient organisation for children and families suffering from the ultra RARE brain disorder Aromatic Amino Acid Decarboxylase deficiency …

PTC Therapeutics | Pioneers in Rare Disease Treatments
Extending life’s moments for children and adults living with rare diseases. PTC is an established global biopharmaceutical company that delivers transformative therapies for people living with …

Learn About AADC Deficiency | AADC Disease
Read about Aromatic L-amino Acid Decarboxylase (AADC) deficiency and better understand the value of early diagnosis.

Aromatic L-Amino Acid Decarboxylase Deficiency
Oct 12, 2023 · DDC encodes aromatic L-amino acid decarboxylase (AADC), a homodimeric pyridoxal 5-prime phosphate (PLP)-dependent enzyme that catalyzes the decarboxylation of L …

AADC | United States | AADC Family Network
Aromatic L-Amino Acid Decarboxylase Deficiency (AADC) is a very rare genetic inborn error of metabolism which affects the biosynthesis and transport of dopamine and serotonin (two …

Therapy for AADCd Deficiency | KEBILIDI™ (eladocagene ...
KEBILIDI is a gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. This indication is approved under ...

Aadc Deficiency Gene Therapy

Aadc Deficiency Gene Therapy

Related Articles

- aba therapy certification nj
- abc method of time management
- aashto guide for development of bicycle facilities

Back to Home